Detalles de la búsqueda
1.
Factors associated with fragility fractures in type 2 diabetes: An analysis of the randomised controlled Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Diabetes Metab Res Rev
; 39(5): e3631, 2023 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-36893361
2.
Review and comparison of retinal vessel calibre and geometry software and their application to diabetes, cardiovascular disease, and dementia.
Graefes Arch Clin Exp Ophthalmol
; 261(8): 2117-2133, 2023 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-36801971
3.
Guideline-based audit of the hospital management of heart failure with reduced ejection fraction.
Intern Med J
; 53(9): 1595-1601, 2023 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35666643
4.
No relationship between socioeconomic status, education level and development and progression of diabetic retinopathy in type 2 diabetes: a FIELD trial substudy.
Intern Med J
; 53(11): 2128-2131, 2023 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-37997276
5.
Relative leucocyte telomere length is associated with incident end-stage kidney disease and rapid decline of kidney function in type 2 diabetes: analysis from the Hong Kong Diabetes Register.
Diabetologia
; 65(2): 375-386, 2022 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-34807303
6.
Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease.
Circulation
; 143(5): 470-478, 2021 02 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-33185476
7.
Hybrid closed-loop therapy with a first-generation system increases confidence and independence in diabetes management in youth with type 1 diabetes.
Diabet Med
; 39(9): e14907, 2022 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-35757899
8.
Fenofibrate, which reduces risk of sight-threatening diabetic retinopathy in type 2 diabetes, is associated with early narrowing of retinal venules: a FIELD trial substudy.
Intern Med J
; 52(4): 676-679, 2022 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-35419960
9.
Effect of evolocumab on acute arterial events across all vascular territories : results from the FOURIER trial.
Eur Heart J
; 42(47): 4821-4829, 2021 12 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-34537830
10.
Efficacy and safety of low-dose colchicine in patients with coronary disease: a systematic review and meta-analysis of randomized trials.
Eur Heart J
; 42(28): 2765-2775, 2021 07 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-33769515
11.
Predicting Benefit From Evolocumab Therapy in Patients With Atherosclerotic Disease Using a Genetic Risk Score: Results From the FOURIER Trial.
Circulation
; 141(8): 616-623, 2020 02 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-31707849
12.
The Effect of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition on the Risk of Venous Thromboembolism.
Circulation
; 141(20): 1600-1607, 2020 05 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-32223429
13.
Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients.
N Engl J Med
; 379(12): 1107-1117, 2018 09 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-30145941
14.
Efficacy and Safety of Long-Term Evolocumab Use Among Asian Subjectsã- A Subgroup Analysis of the Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk (FOURIER) Trial.
Circ J
; 85(11): 2063-2070, 2021 10 25.
Artículo
en Inglés
| MEDLINE | ID: mdl-33980763
15.
Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial.
Circulation
; 139(3): 366-375, 2019 01 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30586726
16.
Lipoprotein(a), PCSK9 Inhibition, and Cardiovascular Risk.
Circulation
; 139(12): 1483-1492, 2019 03 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-30586750
17.
Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis.
Stroke
; 51(5): 1546-1554, 2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32312223
18.
Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.
N Engl J Med
; 376(18): 1713-1722, 2017 05 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-28304224
19.
Uric acid predicts long-term cardiovascular risk in type 2 diabetes but does not mediate the benefits of fenofibrate: The FIELD study.
Diabetes Obes Metab
; 22(8): 1388-1396, 2020 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-32243036
20.
Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Circulation
; 137(4): 338-350, 2018 01 23.
Artículo
en Inglés
| MEDLINE | ID: mdl-29133605